Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Nature Medicine

• Publication date

  2008-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nm.1891PMID 19029980
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PML targeting eradicates quiescent leukaemia-initiating cells

  2009cited by this paper
• Erratum: BMP type I receptor inhibition reduces heterotopic ossification

  2009cited by this paper
• Corrigendum : Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

  2009cited by this paper
• Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway

  2008cited by this paper
• Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha.

  2008cited by this paper
• Faculty Opinions recommendation of Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.

  2008cited by this paper
• Acute promyelocytic leukemia: from highly fatal to highly curable.

  2008cited by this paper
• PML targeting eradicates quiescent leukaemia-initiating cells

  2008cited by this paper
• Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor alpha

  2007cited by this paper
• Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.

  2007cited by this paper
• Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation.

  2007cited by this paper
• RXR is an essential component of the oncogenic PML/RARA complex in vivo.

  2007cited by this paper
• Role of the polycomb repressive complex 2 in acute promyelocytic leukemia.

  2007cited by this paper
• Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

  2006cited by this paper
• RARγ is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation

  2006cited by this paper
• Rexinoid-triggered differentiation and tumor-selective apoptosis of AML by protein kinase A-mediated de-subordination of RXR

  2006cited by this paper
• Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7.

  2006cited by this paper
• Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series

  2006cited by this paper
• Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors.

  2006cited by this paper
• Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization.

  2006cited by this paper
• A sumoylation site in PML/RARA is essential for leukemic transformation.

  2005cited by this paper
• Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.

  2005cited by this paper
• Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia.

  2005cited by this paper
• Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.

  2005cited by this paper
• Cancer stem cells: lessons from leukemia.

  2005cited by this paper
• Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.

  2005cited by this paper
• How patients have benefited from mouse models of acute promyelocytic leukaemia

  2005cited by this paper
• Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.

  2004cited by this paper
• All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

  2004cited by this paper
• Phosphodiesterase IV Inhibition by Piclamilast Potentiates the Cytodifferentiating Action of Retinoids in Myeloid Leukemia Cells

  2004cited by this paper
• All-trans retinoic acid As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

  2004cited by this paper
• Essential role of Plzf in maintenance of spermatogonial stem cells

  2004cited by this paper
• PML–RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation

  2004cited by this paper
• Neutrophil Elastase Cleaves PML-RAR and Is Important for the Development of Acute Promyelocytic Leukemia in Mice

  2003cited by this paper
• Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia

  2002cited by this paper
• In Vivo Activation of cAMP Signaling Induces Growth Arrest and Differentiation in Acute Promyelocytic Leukemia

  2002cited by this paper
• Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor

  2002cited by this paper
• How acute promyelocytic leukaemia revived arsenic

  2002cited by this paper
• Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission

  2001cited by this paper
• Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor α Degradation

  2001cited by this paper
• Two critical hits for promyelocytic leukemia.

  2000cited by this paper
• Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.

  2000cited by this paper
• Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins

  1999cited by this paper
• Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient

  1999cited by this paper
• Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.

  1999cited by this paper
• Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

  1999cited by this paper
• Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia

  1999cited by this paper
• Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

  1999cited by this paper
• Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins.

  1999cited by this paper
• Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia

  1999cited by this paper
• Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

  1998cited by this paper
• Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL

  1998cited by this paper
• Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.

  1998cited by this paper
• Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.

  1998cited by this paper
• [Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia].

  1997cited by this paper
• Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia.

  1997cited by this paper
• Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia.

  1997cited by this paper
• Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

  1996cited by this paper
• Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1.

  1996influential reference
• Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia.

  1995cited by this paper
• Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line.

  1994cited by this paper
• Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.

  1992cited by this paper

• Management Challenges of Acute Promyelocytic Leukemia in Pregnancy: A Case Report.

  2026cites this paper
• 急性早幼粒细胞白血病的治愈之路与中国贡献

  2025cites this paper
• The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemia

  2025cites this paper
• Enlarged PML-nuclear bodies trigger conflicting cell cycle signal-mediated cytotoxicity in leukemia cells

  2025cites this paper
• A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.

  2025cites this paper
• Advances of RARα fusion genes in acute promyelocytic leukemia.

  2025cites this paper
• Autophagy Inhibition–induced Cytosolic DNA Sensing Combined with Differentiation Therapy Induces Irreversible Myeloid Differentiation in Leukemia Cells

  2024cites this paper
• ATRA-induced NEAT1 upregulation promotes autophagy during APL cell granulocytic differentiation

  2024cites this paper
• Enhanced Detection of Novel Low-Frequency Gene Fusions via High-Yield Ligation and Multiplexed Enrichment Sequencing.

  2024cites this paper
• Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery

  2024cites this paper
• Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy in patients with newly diagnosed glioblastoma

  2024cites this paper
• History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies

  2024cites this paper
• Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studies.

  2024cites this paper
• The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away

  2023influential citation
• Silymarin in combination with ATRA enhances apoptosis induction in human acute promyelocytic NB4 cells.

  2023cites this paper
• UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability

  2023cites this paper
• Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy

  2023cites this paper
• Mechanistic update of Trisenox in blood cancer

  2023cites this paper
• High-fat diet promotes Acute Promyelocytic Leukemia through PPARδ-enhanced self-renewal of preleukemic progenitors

  2022cites this paper
• APL: Nemo finds its sea anemone.

  2022cites this paper
• A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify®

  2022cites this paper
• Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets.

  2022cites this paper
• Challenges and future directions

  2022cites this paper
• Single-cell multi-omics analyses reveal EZH2 as a main driver of retinoic acid resistance in PLZF-RARA leukemia

  2022cites this paper
• Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias

  2022cites this paper
• Zinc controls PML nuclear body formation through regulation of a paralog specific auto-inhibition in SUMO1

  2022cites this paper
• Identification of Transcription Factors Regulating SARS-CoV-2 Tropism Factor Expression by Inferring Cell-Type-Specific Transcriptional Regulatory Networks in Human Lungs

  2022cites this paper
• Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication

  2022cites this paper
• How Retinoic Acid and Arsenic Transformed Acute Promyelocytic Leukemia Therapy.

  2022cites this paper
• Acute Promyelocytic Leukemia: Simplifying Treatment in a Resource Poor Setting

  2021cites this paper
• Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells

  2021cites this paper
• Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells

  2021cites this paper
• Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency

  2021cites this paper
• Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells

  2021cites this paper
• A novel fusion protein TBLR1-RARα acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies

  2021cites this paper
• Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia

  2021cites this paper
• (–)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1

  2021cites this paper
• Retinoids in haematology : a timely revival?

  2021cites this paper
• PML-RARα: changing myeloid networks.

  2021cites this paper
• How I Treat Acute Promyelocytic Leukemia

  2021cites this paper
• Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia.

  2021cites this paper
• Arsenic Trioxide Promotes Tumor Progression by Inducing the Formation of PGCCs and Embryonic Hemoglobin in Colon Cancer Cells

  2021cites this paper
• Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy

  2021cites this paper
• PML/RARA destabilization by hyperthermia: a new model for oncogenic fusion protein degradation?

  2021cites this paper
• The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells

  2021cites this paper
• Classic and Variants APLs, as Viewed from a Therapy Response

  2020cites this paper
• Depleting interferon regulatory factor‐1(IRF‐1) with CRISPR/Cas9 attenuates inducible oxidative metabolism without affecting RA‐induced differentiation in HL‐60 human AML cells

  2020cites this paper
• Acute promyelocytic leukemia (APL): a review of the literature

  2020cites this paper
• Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation

  2020cites this paper
• When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia

  2020cites this paper
• Targeting DUBs to degrade oncogenic proteins

  2020cites this paper
• Identification of chlorprothixene as a potential drug that induces apoptosis and autophagic cell death in acute myeloid leukemia cells

  2020cites this paper
• Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

  2020cites this paper
• Primaquine phosphate induces the apoptosis of ATRA‐resistant acute promyelocytic leukemia cells by inhibition of the NF‐κB pathway

  2020cites this paper
• A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.

  2020cites this paper
• All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells

  2020cites this paper
• Selective autophagy in normal and malignant hematopoiesis.

  2020cites this paper
• Depleting interferon regulatory factor-1(IRF-1) with CRISPR/ Cas9 attenuates inducible oxidative metabolism without affecting RA-induced differentiation in HL-60 human AML cells

  2020cites this paper
• Definition of a Small Core Transcriptional Circuit Regulated by AML1-ETO

  2020cites this paper
• Protein Sumoylation with SUMO1 Promoted by Pin1 in Glioma Stem Cells Augments Glioblastoma Malignancy.

  2020cites this paper
• A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide

  2020cites this paper
• Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia

  2020cites this paper
• MiR-15b regulates cell differentiation and survival by targeting CCNE1 in APL cell lines.

  2019cites this paper
• Hugues de Thé

  2019cites this paper
• VITAMIN A, RETINOIC ACID AND TAMIBAROTENE, A FRONT TOWARD ITS ADVANCES: A REVIEW

  2019cites this paper
• Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma.

  2019cites this paper
• THE ROLE OF THE CELL SURFACE PROTEASE RECEPTOR S100A10 IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) AND ITS REGULATION BY RETINOIC ACID THERAPY

  2019cites this paper
• Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia

  2019cites this paper
• FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

  2019cites this paper
• Novel mechanistic insights into the anti-cancer mode of arsenic trioxide.

  2019cites this paper
• Curative strategies in APL.

  2019cites this paper
• Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies

  2019cites this paper
• Arsenic in Rice Grain: Role of Transporters in Arsenic Accumulation

  2019cites this paper
• Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia.

  2019cites this paper
• Identification of drugs for leukaemia differentiation therapy by network pharmacology

  2019cites this paper
• Characterization of atypical acute promyelocytic leukaemia

  2019influential citation
• Advances in precision epigenetic treatment for acute promyelocytic leukemia.

  2019cites this paper
• Inhibition of the Hedgehog pathway in lung cancer.

  2019cites this paper
• Vitamin A,retinoic acid and retinoid pharmacology,From front move center

  2019cites this paper
• Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1

  2019cites this paper
• Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors

  2019cites this paper
• Identification and characterization of the RIG-I helicase partners involved in the balance proliferation / cell differentiation. Characterization of G-quadruplex resolving by the helicase Pif1 in Bacteroides sp 3_1_23.

  2018cites this paper
• The Leukemic Stem Cell

  2018cites this paper
• Low-Dose Arsenic Trioxide Modulates the Differentiation of Mouse Embryonic Stem Cells.

  2018cites this paper
• Molecular Genetics of APL

  2018cites this paper
• Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia

  2018cites this paper
• Arsenic-Based Anticancer-Combined Therapy: Novel Mechanism Inducing Apoptosis of Cancer Cells

  2018cites this paper
• Molecular Targets of Treatment in APL

  2018cites this paper
• Acute Promyelocytic Leukemia

  2018cites this paper
• Differentiation therapy revisited

  2018cites this paper
• Acute promyelocytic leukemia lacking t(15;17): molecular evidence of atypical PML/RAR- α transcriptional variant by gene sequencing Akutna promijelocitna leukemija bez t(15;17): molekularni dokazi atipi č ne PML/RAR- α transkripcione varijante genskim sekvenciranjem

  2018cites this paper
• Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

  2018cites this paper
• Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4)

  2018cites this paper
• Long Term Follow up of Patients with Advanced Cancers after Chemotherapy and Traditional Medicine (82 Cases)

  2018cites this paper
• TREATMENT OF PATIENTS WITH ADVANCED CANCER FOLLOWING CHEMOTHERAPY AND TRADITIONAL MEDICINE - LONG TERM FOLLOW UP OF 75 CASES

  2018cites this paper
• Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

  2018cites this paper
• Modulation of the haematopoietic stem cell niche by photo-triggerable nanoparticles

  2018cites this paper
• Deubiquitinase USP48 promotes ATRA-induced granulocytic differentiation of acute promyelocytic leukemia cells.

  2018cites this paper
• Targeting GLI Transcription Factors in Cancer

  2018cites this paper
• Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)☆

  2018cites this paper